A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
Biopharma Leaders M&A Didn’t Deliver as Expected in 2024: Biopharma Turns to JPMorgan Healthcare Conference for Optimism Biopharma Leaders the much-anticipated mergers and acquisitions (M&A) wave that the biopharma industry hoped would materialize in 2024 did not arrive as expected,…
Propranolol Reduces Tremors in Parkinson’s Disease: Insights into the Role of Stress and the Brain Parkinson’s disease is a progressive neurodegenerative disorder that affects movement, often leading to symptoms such as tremors, stiffness, and slowness of movement. Tremors, in particular,…
The World Health Organization (WHO) has expressed deep dismay following the raid on Kamal Adwan Hospital, which has rendered the last major health facility in North Gaza non-operational. This attack underscores the systematic dismantling of the region’s health infrastructure, coupled…
Aetna , a CVS Health® company , has enhanced the functionality of its Aetna Health℠ app to offer Spanish language support for all eligible health plan members, regardless of their coverage type or location. This update is designed to improve…
Merck known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg mg)] in adults with HIV-1 infection…
Hansoh Pharma has granted MSD (the tradename of Merck & Co., Inc., Rahway, N.J., USA) an exclusive global license for HS-10535, its investigational oral small molecule GLP-1 receptor agonist. This collaboration represents a significant step in advancing therapies for cardiometabolic…
Eli Lilly and Company announced today that China’s National Medical Products Administration (NMPA) has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Lilly’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease. This includes individuals…
Merck known as MSD outside of the United States and Canada, has announced the discontinuation of clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab was being evaluated in combination with pembrolizumab (KEYTRUDA®) in the…
Takeda is hosting an investor R&D Day today, starting at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage pipeline, focusing on its transformative potential for patients and the market opportunities these therapies present. Christophe Weber, Takeda’s…
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) at six years for patients…
Celltrion has announced that Health Canada has approved Omlyclo™, the first and only biosimilar referencing Xolair® (omalizumab) in Canada. Omlyclo™ is now authorized for the treatment of adults and adolescents with chronic idiopathic urticaria (CIU), also known as chronic spontaneous…